• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

FDA

anonymous

Guest
Do you think the FDA would care that Novo allows, and has for some time, reps to sample Oz and Rybelsus to weight treatment centers? Always love how RBDs, DBMs, reps feign ethics but have no problem cashing in on selling off-label.
 

<















Do you think the FDA would care that Novo allows, and has for some time, reps to sample Oz and Rybelsus to weight treatment centers? Always love how RBDs, DBMs, reps feign ethics but have no problem cashing in on selling off-label.
False news, at least in our region this is strictly monitored. either way, not going to go through unless pt is T2D
 








Do you think the FDA would care that Novo allows, and has for some time, reps to sample Oz and Rybelsus to weight treatment centers? Always love how RBDs, DBMs, reps feign ethics but have no problem cashing in on selling off-label.
Nothing to “cash in on” that ship sailed. Goals are packed tight to run a bonus bell curve.
 




The FDA knows that. There is no law restricting prescribing off label use, only promoting off label use is illegal. Novo, as a whole, does a good job NOT promoting off label. Let’s be honest, do they even need to with this level of brand exposure? Absolutely not….